Marc Van Bilsen

Associate professor

Dr Marc van Bilsen obtained a Master degree in Cellular Biology (University of Leiden) in 1982, and received his PhD degree at the Department of Physiology of the Faculty of Medicine of the Maastricht University in 1988, where he studied the relation between cardiac lipid metabolism and tissue injury during myocardial ischemia and reperfusion. As a post-doc, he worked at the University California, San Diego, CA (UCSD), as a recipient of NATO-Science Fellowship award (NWO) and an American Heart Association award, on the regulation of gene transcription in cardiac hypertrophy (1990–1992). After his return to Maastricht he was appointed as Senior Investigator of the Royal Dutch Academy of Science (KNAW, 1993-1998). In 1998, he was awarded the Edmond Hustinx Price for Science by the Maastricht University and became appointed as Established Investigator by the Dutch Heart Foundation (NHS,1998-2003) to continue his studies on cardiac metabolism in hypertrophy, especially on the role of fatty acids as signaling molecules and regulators of cardiac gene expression. Since 1998, he holds the position of Associate Professor in Molecular Physiology at the Faculty of Medicine of the Maastricht University.

Furthermore, he is currently appointed Chairman of the CARIM Education Programme Committee (EPC) and acts as PhD Coordinator for the CARIM graduate programme.

He has been principal investigator on several national and international grants on the topic of cardiac metabolic remodeling, including a Netherlands Organisation for Scientific Research (NWO) TOP-Program Grant (2004-2009) and an European integratedproject (EUGeneHeart, FP6 LifeSciHealth, 2006-2011). He (co)authored over 120 papers in the cardiovascular field. His current research interest focusses on the interplay between cardiac metabolism and inflammation in the development of cardiometabolic disease in general, and in heart failure with preserved ejection fraction (HFpEF) in particular.

Department of Physiology
Universiteitsingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: 3.156
T: +31(0)43 388 12 04

  • 2020
    • Cuijpers, I., Simmonds, S. J., van Bilsen, M., Czarnowska, E., Miqueo, A. G., Heymans, S., Kuhn, A. R., Mulder, P., Ratajska, A., Jones, E. A., & Brakenhielm, E. (2020). Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. Basic Research in Cardiology, 115(4), [39]. https://doi.org/10.1007/s00395-020-0798-y
    • Verdonschot, J. A. J., Wang, P., Van Bilsen, M., Hazebroek, M. R., Merken, J. J., Vanhoutte, E. K., Henkens, M. T. H. M., Van Den Wijngaard, A., Glatz, J. F. C., Krapels, I. P. C., Brunner, H. G., Heymans, S. R. B., & Bierau, J. (2020). Metabolic Profiling Associates with Disease Severity in Nonischemic Dilated Cardiomyopathy. Journal of Cardiac Failure, 26(3), 212-222. https://doi.org/10.1016/j.cardfail.2019.09.004
  • 2019
    • Verjans, R., Derks, W. J. A., Korn, K., Soennichsen, B., van Leeuwen, R. E. W., Schroen, B., van Bilsen, M., & Heymans, S. (2019). Functional Screening Identifies MicroRNAs as Multi-Cellular Regulators of Heart Failure. Scientific Reports, 9, [6055]. https://doi.org/10.1038/s41598-019-41491-9
    • Rech, M., Kuhn, A. R., Lumens, J., Carai, P., van Leeuwen, R., Verhesen, W., Verjans, R., Lecomte, J., Liu, Y., Luiken, J. J. F. P., Mohren, R., Cillero-Pastor, B., Heymans, S., Knoops, K., van Bilsen, M., & Schroen, B. (2019). AntagomiR-103 and-107 Treatment Affects Cardiac Function and Metabolism. Molecular Therapy - Nucleic Acids, 14, 424-437. https://doi.org/10.1016/j.omtn.2018.12.010
  • 2018
    • Aizpurua, A. B., Schroen, B., van Bilsen, M., & van Empel, V. (2018). Targeted HFpEF therapy based on matchmaking of human and animal models. American Journal of Physiology-heart and Circulatory Physiology, 315(6), H1670-H1683. https://doi.org/10.1152/ajpheart.00024.2018
    • Hermans-Beijnsberger, S., van Bilsen, M., & Schroen, B. (2018). Long non-coding RNAs in the failing heart and vasculature. Non-coding RNA research, 3(3), 118-130. https://doi.org/10.1016/j.ncrna.2018.04.002
    • Remels, A. H. V., Derks, W. J. A., Cillero-Pastor, B., Verhees, K. J. P., Kelders, M. C., Heggermont, W., Carai, P., Summer, G., Ellis, S. R., de Theije, C. C., Heeren, R. M. A., Heymans, S., Papageorgiou, A. P., & van Bilsen, M. (2018). NF-kappa B-mediated metabolic remodelling in the inflamed heart in acute viral myocarditis. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1864(8), 2579-2589. https://doi.org/10.1016/j.bbadis.2018.04.022
    • Sorop, O., Heinonen, I., van Kranenburg, M., van de Wouw, J., de Beer, V. J., Nguyen, I. T. N., Octavia, Y., van Duin, R. W. B., Stam, K., van Geuns, R-J., Wielopolski, P. A., Krestin, G. P., van den Meiracker, A. H., Verjans, R., van Bilsen, M., Danser, A. H. J., Paulus, W. J., Cheng, C., Linke, W. A., ... Duncker, D. J. (2018). Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. Cardiovascular Research, 114(7), 954-964. https://doi.org/10.1093/cvr/cvy038
    • Rech, M., Aizpurua, A. B., van Empel, V., van Bilsen, M., & Schroen, B. (2018). Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle. Cardiovascular Research, 114(6), 782-793. https://doi.org/10.1093/cvr/cvy049
    • Verdonschot, J. A. J., Hazebroek, M. R., Derks, K. W. J., Aizpurua, A. B., Merken, J. J., Wang, P., Bierau, J., van den Wijngaard, A., Schalla, S. M., Hamid, M. A. A., van Bilsen, M., van Empel, V. P. M., Knackstedt, C., Brunner-La Rocca, H-P., Brunner, H. G., Krapels, I. P. C., & Heymans, S. R. B. (2018). Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-termlife-threatening arrhythmias. European Heart Journal, 39(10), 864-873. https://doi.org/10.1093/eurheartj/ehx808